Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

COMPARISON OF PRIMARY HUMAN HEPATOCYTES AND HEPATOMA CELL LINE HEPG2 WITH REGARD TO THEIR BIOTRANSFORMATION PROPERTIES

Stefan Wilkening, Frank Stahl and Augustinus Bader
Drug Metabolism and Disposition August 2003, 31 (8) 1035-1042; DOI: https://doi.org/10.1124/dmd.31.8.1035
Stefan Wilkening
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Stahl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Augustinus Bader
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Cultures of primary hepatocytes and hepatoma cell line HepG2 are frequently used in in vitro models for human biotransformation studies. In this study, we characterized and compared the capacity of these model systems to indicate the presence of different classes of promutagens. Genotoxic sensitivity, enzyme activity, and gene expression were monitored in response to treatment with food promutagens benzo[a]pyrene, dimethylnitrosamine (DMN), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). DNA damage could be detected reliably with the comet assay in primary human hepatocytes, which were maintained in sandwich culture. All three promutagens caused DNA damage in primary cells, but in HepG2 no genotoxic effects of DMN and PhIP could be detected. We supposed that the lack of specific enzymes accounts for their inability to process these promutagens. Therefore, we quantified the expression of a broad range of genes coding for drug-metabolizing enzymes with real-time reverse transcription-polymerase chain reaction. The genes code for cytochromes P450 and, in addition, for a series of important phase II enzymes. The expression level of these genes in human hepatocytes was similar to those previously reported for human liver samples. On the other hand, expression levels in HepG2 differed significantly from that in human. Activity and expression, especially of phase I enzymes, were demonstrated to be extremely low in HepG2 cells. Up-regulation of specific genes by test substances was similar in both cell types. In conclusion, human hepatocytes are the preferred model for biotransformation in human liver, whereas HepG2 cells may be useful to study regulation of drug-metabolizing enzymes.

Footnotes

  • ↵1 Abbreviations used are: B[a]P, benzo[a]pyrene; PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; DMN, dimethylnitrosamine; RT-PCR, reverse transcription-polymerase chain reaction; DMSO, dimethyl sulfoxide; 3-MC, 3-methylcholanthrene; PBS, phosphate-buffered saline; EROD, 7-ethoxyresorufin O-deethylation; ECOD, 7-ethoxycoumarin O-deethylation; NAT, N-acetyltransferase; HMBS, hydroxymethylbilane synthase; HPRT, hypoxanthine phosphoribosyltransferase; ATP5O, ATP synthase; EF1A1, elongation factor 1 alpha; NQO1, NADP-quinone reductase 1; SULT, sulfotransferase; GAPD, glyceraldehyde-3-phosphate dehydrogenase; LAP, liver-enriched activator protein; LIP, liver-enriched inhibitor protein; C/EBP, CCAAT/enhancer-binding protein.

  • This work was supported by the European Union, HEPADNA Contract QLRT-1999-00810 and by a fellowship from the Dr. Hilmer-Stiftung for S.W.

    • Received February 26, 2003.
    • Accepted April 24, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (8)
Drug Metabolism and Disposition
Vol. 31, Issue 8
1 Aug 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
COMPARISON OF PRIMARY HUMAN HEPATOCYTES AND HEPATOMA CELL LINE HEPG2 WITH REGARD TO THEIR BIOTRANSFORMATION PROPERTIES
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

COMPARISON OF PRIMARY HUMAN HEPATOCYTES AND HEPATOMA CELL LINE HEPG2 WITH REGARD TO THEIR BIOTRANSFORMATION PROPERTIES

Stefan Wilkening, Frank Stahl and Augustinus Bader
Drug Metabolism and Disposition August 1, 2003, 31 (8) 1035-1042; DOI: https://doi.org/10.1124/dmd.31.8.1035

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

COMPARISON OF PRIMARY HUMAN HEPATOCYTES AND HEPATOMA CELL LINE HEPG2 WITH REGARD TO THEIR BIOTRANSFORMATION PROPERTIES

Stefan Wilkening, Frank Stahl and Augustinus Bader
Drug Metabolism and Disposition August 1, 2003, 31 (8) 1035-1042; DOI: https://doi.org/10.1124/dmd.31.8.1035
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Determination of Acyl-, O-, and N-Glucuronide
  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics